Stock Ratings from Analyst Ratings Network

Open Main Menu Open Sidebar

Mirati Therapeutics Company Profile (NASDAQ:MRTX)

Consensus Ratings for Mirati Therapeutics (NASDAQ:MRTX) (?)
Ratings Breakdown: 1 Hold Rating(s), 4 Buy Rating(s), 1 Strong Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $27.10 (49.15% upside)

Analysts' Ratings History for Mirati Therapeutics (NASDAQ:MRTX)
Show:
DateFirmActionRatingPrice TargetDetailsShare
7/11/2014Johnson RiceUpgradeOverweight -> Focus ListViewTweet This Rating  Share This Rating on StockTwits
7/8/2014Brean CapitalInitiated CoverageBuy$27.00ViewTweet This Rating  Share This Rating on StockTwits
6/16/2014JMP SecuritiesReiterated RatingMarket Outperform$25.00 -> $28.00ViewTweet This Rating  Share This Rating on StockTwits
4/10/2014ZacksUpgradeUnderperform -> Neutral$19.40ViewTweet This Rating  Share This Rating on StockTwits
3/18/2014Brean CapitalBoost Price TargetBuy$20.00 -> $27.00ViewTweet This Rating  Share This Rating on StockTwits
3/12/2014ZacksDowngradeNeutral -> Underperform$19.90ViewTweet This Rating  Share This Rating on StockTwits
3/4/2014Jefferies GroupLower Price Target$36.00 -> $34.00ViewTweet This Rating  Share This Rating on StockTwits
1/1/2014ZacksUpgradeUnderperform -> Neutral$17.00ViewTweet This Rating  Share This Rating on StockTwits
12/18/2013Jefferies GroupInitiated CoverageBuy$36.00ViewTweet This Rating  Share This Rating on StockTwits
11/18/2013ZacksDowngradeNeutral -> Underperform$16.50ViewTweet This Rating  Share This Rating on StockTwits
11/14/2013JMP SecuritiesBoost Price TargetMarket Outperform$19.00 -> $25.00ViewTweet This Rating  Share This Rating on StockTwits
11/4/2013Leerink SwannInitiated CoverageOutperformViewTweet This Rating  Share This Rating on StockTwits
9/23/2013ZacksDowngradeOutperform -> Neutral$17.10ViewTweet This Rating  Share This Rating on StockTwits
8/15/2013Piper JaffrayInitiated CoverageOverweightViewTweet This Rating  Share This Rating on StockTwits
(Data available from 8/1/2012 forward)